Salvage treatment in IDH1 mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase:A case report  

作　　者：Dan Li Shuqi Zhao Liping Mao Jie Jin Jinghan Wang 

机构地区：[1]Department of Hematology,Shaoxing People's Hospital,Shaoxing,Zhejiang 312000,China [2]Department of Hematology,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang 310003,China

出　　处：《Genes & Diseases》2023年第6期2215-2217,共3页基因与疾病（英文）

摘　　要：Acute myeloid leukemia(AML)and acute lymphoblastic leukemia(ALL)are distinct subtypes of acute leukemia with respect to clinical and genetic features.Recently,ALLs were reported to share similar genes like IDH1 mutations to AMLs.1 Specifically,mutated IDH1(5%-15%)frequently occurs in AML and scarcely(1.9%)in ALL.1 Notably,IDH1 along with SRSF2mutation often exists in secondaryAMLpatients and confers a poor prognosis.Recently,venetoclax(VEN)has been demonstrated extremely effective in combination with a hypomethylating agent or chemotherapy for IDH1 mutated AML patients.However,whether VEN combining chemotherapy is effective among ALL patients with similar genetic features to AML remains unclear.Here,we successfully rescued a relapsed ALL case with IDH1 mutation by VEN plus methotrexate and pegaspargase based on their antimetabolic pathways.

关 键 词：IDH1 METHOTREXATE CHEMOTHERAPY 

分 类 号：R73[医药卫生—肿瘤]